These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33181644)

  • 21. The effect of trifluridine/tipiracil for patients with heavily pretreated metastatic gastric cancer: A protocol for systematic review and meta-analysis.
    He X; Zhang T; Wu L; Wu Y; Zhou X
    Medicine (Baltimore); 2021 Jan; 100(2):e24110. PubMed ID: 33466182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment with cinacalcet in secondary hyperparathyroidism for dialysis patients: The will is good--but what about the evidence?].
    Bárány P; Elinder CG; Samuelsson O
    Lakartidningen; 2013 Aug 21-Sep 3; 110(34-35):1481-3. PubMed ID: 24044187
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study.
    Akizawa T; Shimazaki R; Shiramoto M; Fukagawa M;
    Clin Drug Investig; 2018 Oct; 38(10):945-954. PubMed ID: 30168004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
    Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.
    Kawata T; Tokunaga S; Murai M; Masuda N; Haruyama W; Shoukei Y; Hisada Y; Yanagida T; Miyazaki H; Wada M; Akizawa T; Fukagawa M
    PLoS One; 2018; 13(4):e0195316. PubMed ID: 29614098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.
    Ketteler M; Martin KJ; Cozzolino M; Goldsmith D; Sharma A; Khan S; Dumas E; Amdahl M; Marx S; Audhya P
    Nephrol Dial Transplant; 2012 May; 27(5):1942-9. PubMed ID: 21931122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy.
    Eandi M; Pradelli L; Iannazzo S; Chiroli S; Pontoriero G
    Pharmacoeconomics; 2010; 28(11):1041-54. PubMed ID: 20936886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etelcalcetide for the treatment of secondary hyperparathyroidism.
    Hamano N; Komaba H; Fukagawa M
    Expert Opin Pharmacother; 2017 Apr; 18(5):529-534. PubMed ID: 28277829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Tai Chi for post-stroke mental disorders and sleep disorders: A protocol for systematic review and meta-analysis.
    Yang F; Lyu D; Yan R; Wang Y; Li Z; Zou Y; Zhang Y
    Medicine (Baltimore); 2018 Sep; 97(39):e12554. PubMed ID: 30278554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
    Friedl C; Zitt E
    Drug Des Devel Ther; 2018; 12():1589-1598. PubMed ID: 29910605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis.
    Chen L; Wang K; Yu S; Lai L; Zhang X; Yuan J; Duan W
    Ren Fail; 2016 Aug; 38(7):1050-8. PubMed ID: 27198474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Rose M; Shepherd J; Harris P; Pickett K; Lord J
    Pharmacoeconomics; 2018 Nov; 36(11):1299-1308. PubMed ID: 29691773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans.
    Narushima K; Maeda H; Shiramoto M; Endo Y; Ohtsuka S; Nakamura H; Nagata Y; Uchimura T; Kannami A; Shimazaki R; Fukagawa M; Akizawa T
    Clin Transl Sci; 2019 Jan; 12(1):20-27. PubMed ID: 30238620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of levetiracetam in children with epilepsy: protocol for an umbrella review of systematic reviews and meta-analyses of randomised controlled trials.
    Gan J; Ma D; Xiong T
    BMJ Open; 2019 Jul; 9(7):e029811. PubMed ID: 31296513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and effectiveness of acupuncture for POSEIDON patients in IVF/ICSI: A protocol for systematic review and meta-analysis.
    Zhu X; Yang L; Li Z; Pan Z; Huang S; Xiong Y; Wu J
    Medicine (Baltimore); 2020 Oct; 99(42):e22768. PubMed ID: 33080745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials.
    Palmer SC; Nistor I; Craig JC; Pellegrini F; Messa P; Tonelli M; Covic A; Strippoli GF
    PLoS Med; 2013; 10(4):e1001436. PubMed ID: 23637579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis.
    Warady BA; Ng E; Bloss L; Mo M; Schaefer F; Bacchetta J
    Pediatr Nephrol; 2020 Sep; 35(9):1679-1697. PubMed ID: 32367309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cinacalcet: a new treatment for secondary hyperparathyroidism in patients receiving hemodialysis.
    Byrnes CA; Shepler BM
    Pharmacotherapy; 2005 May; 25(5):709-16. PubMed ID: 15899733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of complementary and alternative medicine in the treatment of autism spectrum disorder: A protocol for systematic review and meta-analysis.
    Shuai B; Jin H; Lin Y; Duan R; Zhao N; Li Z; Mao J; Luo Y; Shi M
    Medicine (Baltimore); 2020 Nov; 99(45):e23128. PubMed ID: 33157993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.